Volume 6, Issue 4, Pages (October 2009)

Slides:



Advertisements
Similar presentations
Volume 42, Issue 2, Pages (February 2015)
Advertisements

Cheng-Ming Sun, Edith Deriaud, Claude Leclerc, Richard Lo-Man  Immunity 
Volume 5, Issue 1, Pages (January 2009)
Volume 135, Issue 5, Pages e1 (November 2008)
The Humoral Immune Response Is Initiated in Lymph Nodes by B Cells that Acquire Soluble Antigen Directly in the Follicles  Kathryn A. Pape, Drew M. Catron,
A Single Domain–Based Anti-Her2 Antibody Has Potent Antitumor Activities  Xiaoqiong Wu, Siqi Chen, Limin Lin, Jiayu Liu, Yanlan Wang, Yumei Li, Qing Li,
Volume 158, Issue 6, Pages (September 2014)
In Vivo Mechanisms of Vaccine-Induced Protection against HPV Infection
Volume 125, Issue 1, Pages (April 2006)
Volume 14, Issue 5, Pages (November 2013)
Hans-Peter Raué, Carol Beadling, Jennifer Haun, Mark K. Slifka 
Volume 6, Issue 2, Pages (August 2009)
Volume 12, Issue 4, Pages (October 2012)
Volume 8, Issue 6, Pages (December 2010)
Volume 6, Issue 5, Pages (November 2009)
Volume 42, Issue 2, Pages (February 2015)
Preventing Allograft Rejection by Targeting Immune Metabolism
Volume 10, Issue 6, Pages (December 2011)
Dynamic Interplay among Monocyte-Derived, Dermal, and Resident Lymph Node Dendritic Cells during the Generation of Vaccine Immunity to Fungi  Karen Ersland,
Volume 20, Issue 3, Pages (September 2016)
Volume 167, Issue 3, Pages e9 (October 2016)
Volume 3, Issue 4, Pages (April 2013)
Volume 4, Issue 4, Pages (October 2008)
Lamp-2a Facilitates MHC Class II Presentation of Cytoplasmic Antigens
Volume 11, Issue 6, Pages (June 2012)
Volume 10, Issue 1, Pages (July 2011)
Volume 20, Issue 4, Pages (October 2016)
B-1a and B-1b Cells Exhibit Distinct Developmental Requirements and Have Unique Functional Roles in Innate and Adaptive Immunity to S. pneumoniae  Karen.
Volume 25, Issue 4, Pages (October 2006)
Interleukin-1β But Not Tumor Necrosis Factor is Involved in West Nile Virus-Induced Langerhans Cell Migration from the Skin in C57BL/6 Mice  Scott N.
Volume 1, Issue 2, Pages (April 2007)
Volume 2, Issue 6, Pages (December 2007)
Volume 44, Issue 3, Pages (March 2016)
Volume 19, Issue 2, Pages (February 2016)
Modified mRNA Vaccines Protect against Zika Virus Infection
Volume 19, Issue 5, Pages (May 2016)
Volume 29, Issue 1, Pages (July 2008)
Volume 16, Issue 6, Pages (August 2016)
Volume 13, Issue 4, Pages (April 2013)
Minimization of Bacterial Size Allows for Complement Evasion and Is Overcome by the Agglutinating Effect of Antibody  Ankur B. Dalia, Jeffrey N. Weiser 
Volume 14, Issue 5, Pages (November 2013)
HDAC5, a Key Component in Temporal Regulation of p53-Mediated Transactivation in Response to Genotoxic Stress  Nirmalya Sen, Rajni Kumari, Manika Indrajit.
Interferon-γ-Responsive Nonhematopoietic Cells Regulate the Immune Response to Mycobacterium tuberculosis  Ludovic Desvignes, Joel D. Ernst  Immunity 
Volume 10, Issue 3, Pages (September 2011)
Volume 6, Issue 6, Pages (December 2009)
Human Dendritic Cells as Targets of Dengue Virus Infection
Volume 37, Issue 3, Pages (September 2012)
Volume 23, Issue 3, Pages (April 2018)
Volume 34, Issue 1, Pages (January 2011)
Volume 5, Issue 1, Pages (January 2009)
Volume 16, Issue 6, Pages (December 2014)
Paula MacGregor, Nicholas J. Savill, Deborah Hall, Keith R. Matthews 
Poxviral B1 Kinase Overcomes Barrier to Autointegration Factor, a Host Defense against Virus Replication  Matthew S. Wiebe, Paula Traktman  Cell Host.
Kevin L. Legge, Thomas J. Braciale  Immunity 
Volume 29, Issue 6, Pages (June 2016)
Cell-Intrinsic IL-27 and gp130 Cytokine Receptor Signaling Regulates Virus-Specific CD4+ T Cell Responses and Viral Control during Chronic Infection 
Volume 16, Issue 1, Pages (July 2014)
Volume 8, Issue 2, Pages (August 2010)
Volume 25, Issue 12, Pages e3 (December 2018)
Volume 21, Issue 1, Pages (January 2017)
Volume 4, Issue 3, Pages (September 2008)
Volume 38, Issue 2, Pages (February 2013)
Volume 26, Issue 6, Pages e4 (February 2019)
Volume 26, Issue 1, Pages e4 (January 2018)
Complement C4 Prevents Viral Infection through Capsid Inactivation
Dissecting the Multifactorial Causes of Immunodominance in Class I–Restricted T Cell Responses to Viruses  Weisan Chen, Luis C. Antón, Jack R. Bennink,
Volume 99, Issue 1, Pages e3 (July 2018)
Volume 10, Issue 1, Pages (July 2011)
Atsushi Yamanaka, Eiji Konishi
Volume 12, Pages (February 2019)
Presentation transcript:

Volume 6, Issue 4, Pages 381-391 (October 2009) Complement Protein C1q Reduces the Stoichiometric Threshold for Antibody-Mediated Neutralization of West Nile Virus  Erin Mehlhop, Steevenson Nelson, Christiane A. Jost, Sergey Gorlatov, Syd Johnson, Daved H. Fremont, Michael S. Diamond, Theodore C. Pierson  Cell Host & Microbe  Volume 6, Issue 4, Pages 381-391 (October 2009) DOI: 10.1016/j.chom.2009.09.003 Copyright © 2009 Elsevier Inc. Terms and Conditions

Figure 1 C1q Augments the Neutralization Potency of Anti-WNV Antibodies (A) Serial dilutions of E16 (murine IgG2b) were incubated with WNV RVP in the presence of media, 5% fresh or heat-inactivated mouse serum prior to infection of Raji cells that express the attachment factor DC-SIGNR (Davis et al., 2006). Forty hours later, cells were fixed and analyzed by flow cytometry for GFP expression. (B) Experiments were performed as described in (A), except mixtures of RVP and E16 were incubated with C1q−/− or C3−/− fresh mouse serum, or purified C1q (50 μg/mL). (C and D) The impact of purified C1q on the neutralizing activity of affinity-purified IgG from naive or WNV-immune mouse serum (C) or convalescent heat-inactivated human serum from WNV-infected patients (D) was assayed as described in (A). In all cases, data are expressed as infectivity relative to conditions in the absence of antibody. Error bars represent the standard error of the mean. The number of independent replicates is indicated in the text. Cell Host & Microbe 2009 6, 381-391DOI: (10.1016/j.chom.2009.09.003) Copyright © 2009 Elsevier Inc. Terms and Conditions

Figure 2 C1q Reduces the Stoichiometric Requirements for Neutralization (A) WNV RVPs that differ with respect to the number of DIII-LR epitopes incorporated into the average virion were produced by genetic complementation. WNV RVPs that incorporate different proportions of WT E proteins (indicated on the right) were incubated with serial dilutions of murine E16 in the absence (left panel) or presence (right panel) of 50 μg/ml purified human C1q protein prior to infection of Raji DC-SIGNR cells. Infection was monitored using flow cytometry as described in Figure 1. (B) The size of the population of RVPs resistant to neutralization by saturating concentrations of murine E16 is summarized for RVPs composed of 100%, 50%, 25%, and 10% WT E proteins. The average of data from four to ten independent experiments performed using four to six different preparations of RVPs is shown; error bars display the standard error of the mean. (C) The size of the resistant fraction observed following the incubation of RVPs composed of 25% WT E proteins with humanized isotypes of E16 in the presence or absence of purified C1q is summarized as described for (B). The average of five experiments using at least four independent preparations of RVPs is presented. (D) To measure the ability of E16 to support ADE in the presence or absence of C1q, complexes of virus, antibody, and complement (where indicated) produced for the experiments described in (A) were also used to infect Fc-γR-expressing K562 cells. Infection was expressed as infectivity relative to conditions in the absence of antibody. Error bars represent the standard error of the mean. Asterisks indicate statistical significance as judged by a paired Student's t test (∗∗p ≤ 0.01; ∗∗∗p < 0.001). Cell Host & Microbe 2009 6, 381-391DOI: (10.1016/j.chom.2009.09.003) Copyright © 2009 Elsevier Inc. Terms and Conditions

Figure 3 C1q Augments Neutralization of Antibodies that Recognize Poorly Accessible Determinants on WNV The efficiency of the maturation of WNV RVPs was manipulated as described previously (Nelson et al., 2008). To reduce the efficiency of virion maturation (immature WNV), WNV RVPs were produced in the presence of ammonium chloride (NH4Cl, 20 mM); an increase in maturation efficiency (mature WNV) was achieved by transfection of RVP-producing cells with a plasmid that expresses the human furin protease. Serial dilutions of the fusion loop-reactive mAb E53 were mixed with RVPs produced using standard approaches (standard WNV, left panel), mature WNV preparations (center panel), and immature WNV preparations (right panel) in the presence (red curves) or absence (blue curves) of purified human C1q protein prior to infection of Raji-DC-SIGNR cells. Forty hours later, cells were fixed and analyzed by flow cytometry for GFP expression. The results are representative of two to three independent experiments. Cell Host & Microbe 2009 6, 381-391DOI: (10.1016/j.chom.2009.09.003) Copyright © 2009 Elsevier Inc. Terms and Conditions

Figure 4 Crosslinking of Antibody Bound to WNV Is Sufficient to Lower the Stoichiometric Threshold for Neutralization WNV RVPs composed of 25% WT E proteins were incubated with serial 4-fold dilutions of murine E16 in the absence or presence of anti-murine antibody-specific IgG, Fab2, or Fab (2 μg/ml). RVP-antibody complexes were used to infect duplicate wells containing Raji DC-SIGNR cells. Infection was monitored using flow cytometry as described in Figure 1. The size of the resistant fraction observed at high concentrations of antibody was enumerated by nonlinear regression analysis and is shown on the y axis. Error bars display the standard error of the mean from two to three independent assays. Cell Host & Microbe 2009 6, 381-391DOI: (10.1016/j.chom.2009.09.003) Copyright © 2009 Elsevier Inc. Terms and Conditions

Figure 5 C1q Augments hu-E16-Mediated Protection In Vivo WT and C1q−/− mice were passively transferred with serial 10-fold reductions in dose (ranging from 67 to 0.067 mg/kg) of E16 subclass-switch variants hu-IgG1 (n ≥ 13 mice/dose), hu-IgG2 (n ≥ 15 mice/dose), hu-IgG3 (n ≥ 14 mice/dose), and an A330L variant of E16 hu-IgG3 (IgG3 A330L) (n ≥ 11 mice/dose) 1 day prior to infection with 102 PFU of WNV and subsequently monitored for morbidity. Survival data from at least three independent experiments were analyzed by log-rank test, and IC50s were calculated by nonlinear regression of survival percentage at each mAb dose. Error bars represent the standard error of the mean. Asterisks indicate statistical significance as judged by analysis of variance and an F test (∗∗p = 0.001). Cell Host & Microbe 2009 6, 381-391DOI: (10.1016/j.chom.2009.09.003) Copyright © 2009 Elsevier Inc. Terms and Conditions